Bristol-Myers Squibb’s Q4 Revenue Hits $12.5B, Growth Portfolio Surges 16%
Bristol-Myers Squibb posted fiscal Q4 revenue of $12.5 billion, up 1%, and growth portfolio sales rose 16% to $7.4 billion as full-year revenue reached $48.2 billion, a 17% increase. Morgan Stanley raised its price target to $40 with an Underweight rating, while Bernstein reiterated Hold at $58.
1. Q4 and Full-Year Sales Performance
Bristol-Myers Squibb reported fiscal Q4 revenue of $12.5 billion, a 1% year-over-year gain, and full-year revenue of $48.2 billion, reflecting solid top-line growth despite market pressures.
2. Growth Portfolio Revenue Drivers
The company’s growth portfolio delivered $7.4 billion in Q4 sales, up 16%, led by strong performance of key immuno‐oncology and cardiovascular therapies.
3. Analyst Price Target Updates
Morgan Stanley lifted its price target to $40 while retaining an Underweight rating, and Bernstein reiterated a Hold rating with a $58 target, citing balanced upside potential.
4. Life Science Cares Partnership
Bristol-Myers Squibb committed $30 million and 30,000 volunteer hours to the Food is Health initiative through 2030, aiming to reduce food insecurity and improve community health outcomes.